Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 4Phase 3 3Phase 1 3

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Head & Neck 1Gynecologic 1

Conditions

Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Cyclophosphamide 143pembrolizumab 127Nivolumab 116Carboplatin 99Dexamethasone 93Rituximab 91Paclitaxel 87Gemcitabine 85Lenalidomide 75Cytarabine 74Radiotherapy 73Cisplatin 70Bevacizumab 64Etoposide 62fludarabine phosphate 58fludarabine 56Ipilimumab 55Docetaxel 54Bortezomib 54Prednisone 49Doxorubicin 48Temozolomide 47Everolimus 46Erlotinib Hydrochloride 46Fluorouracil 44Azacitidine 44Capecitabine 43Calcium Dobesilate 43Filgrastim 42Melphalan 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × Alpelisib × Clear all
NCT03284957 2025-11-24

AMEERA-1

Sanofi

Phase 1/2 Terminated
136 enrolled 60 charts
Breast

Breast Neoplasms

NCT02379247 2022-06-07

BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

University of Kansas Medical Center

Phase 1/2 Completed
43 enrolled 18 charts
Breast

Breast Neoplasms

NCT01602315 2020-12-29

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Novartis

Phase 1/2 Terminated
179 enrolled 38 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hereditary Sensory and Autonomic Neuropathies

NCT01708161 2018-09-13

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

Novartis

Phase 1/2 Terminated
47 enrolled 23 charts
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡